Origen Therapeutics, Inc. Receives $2 Million ATP Grant to Advance Technology for Discovery and Production of Human Polyclonal Antibodies from Transgenic Chickens

Published: Oct 03, 2007

BURLINGAME, Calif.--(BUSINESS WIRE)--Origen Therapeutics today announced that the company has been awarded an Advanced Technology Program (ATP) grant totaling $2 million from the National Institute of Standards and Technology (NIST), a division of the U.S. Department of Commerce. The three year grant will help fund development of a new method for discovering and producing human polyclonal antibodies to treat human disease by inserting complex genetic modifications into the chicken genome, enabling the chickens to deposit large amounts of the therapeutic antibodies into their eggs. Origen’s first objective will be to develop polyclonal antibodies to treat antibiotic-resistant infections like Staphylococcus aureus in intensive care units, a growing issue for many hospitals.

Back to news